RT Journal Article
SR Electronic
T1 Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.03.21259949
DO 10.1101/2021.07.03.21259949
A1 Wey, Emmanuel Q
A1 Bristow, Clare
A1 Nandani, Aarti
A1 O’Farrell, Bryan
A1 Pang, Jay
A1 Lanzman, Marisa
A1 Yang, Shuang
A1 Ho, Soo
A1 Mack, Damien
A1 Spiro, Michael
A1 Balakrishnan, Indran
A1 Bhagani, Sanjay
A1 Pollara, Gabriele
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.03.21259949.abstract
AB C-reactive protein (CRP) levels are elevated following bacterial infections but may be attenuated by the IL-6-receptor antagonist tocilizumab. In hospitalised COVID-19 patients, tocilizumab induced a transient (<21 day) fall in CRP but retained CRP responses to nosocomial blood stream infections, and therefore its utility in guiding antibiotic prescribing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding supported this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the Royal Free Hospital NHS Trust's Research and Innovation Group, which serves as the local Institutional Review Board. It stated that the current project was a retrospective audit of routine clinical care and anonymised clinical data being analysed for service development purposes, and that therefore further formal ethical approval was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data analysed in the manuscript are depicted in the figures. Anonymised raw data are available upon request from the corresponding author.